Triple therapy has been recommended as the most effective treatment for Helicobacter pylori eradication. Despite achieving a comparatively high eradication result, however, around 10% of patients still fail to be cured. (Gut 1995; 37: 477 -481) 
Abstract
Triple therapy has been recommended as the most effective treatment for Helicobacter pylori eradication. Despite achieving a comparatively high eradication result, however, around 10% of patients still fail to be cured. Omeprazole can enhance efficacy of single and double antibiotic protocols and is particularly effective when combined with clarithromycin and a nitroimidazole. This study examined the effect of combining triple therapy with omeprazole. A prospective, randomised, unblinded, single centre trial was carried out on consecutive patients with symptoms of dyspepsia and H pylori infection confirmed by rapid urease test, microbiological culture, and histological assessment. Patients were given a five times/day, 12 Eradication of Helicobacter pylori is of importance in achieving a cure of duodenal and gastric ulcer disease. However, the ideal therapeutic regimen for its eradication remains elusive. Triple therapy, using bismuth subcitrate, metronidazole, and tetracycline or amoxycillin achieves the highest eradication resultsl and has therefore been recommended as the preferable treatment for ulcer disease.2
Even with this combination of three drugs active against H pylori, around 1 0% of patients fail to be cured of the infection.3 The reasons for failure are unclear, but compliance and metronidazole resistance are thought to be of importance.3
When studying H pylori eradication in patients in whom seemingly adequate treatment with triple therapy had failed to cure the infection,4 we found that addition of omeprazole to triple therapy (quadruple therapy) cured overall 78% of those infected. Furthermore, addition of omeprazole to monotherapy, such as amoxycillin, was known to improve H pylori eradication with success ranging from 30-80%. The few studies available on omeprazole combined with dual therapy also suggest eradication enhancement ranging from 43% to over 90%.1 2 6-10 Studies combining omeprazole with triple therapy as first line of treatment have suggested consistently high eradication in excess of 90/oO.ll 12 There has been no formal prospective work, however, to look for any positive contribution that omeprazole might give to the already high eradication rates achieved by triple therapy currently given with H2 receptor antagonists. In this study we examine the effect of adding omeprazole to triple therapy and contrast this with the addition of famotidine to triple therapy, which is used routinely in our standard clinical protocol.
Methods

Patients
The study was a prospective, randomised, unblinded, single centre trial carried out on patients with dyspepsia referred to the Centre for Digestive Diseases. Dyspepsia symptoms included epigastric pain or discomfort, nausea, vomiting, eructation, bloating or heartburn.eradication was clinically judged to be of benefit to the patient. A proportion of the patients suffering from non-ulcer dyspepsia or oesophagitis in whom other treatments had failed were included in the study as there is preliminary evidence that in subgroups of such categories symptomatic benefit can occur.13 14 Another significant subgroup of patients had been diagnosed previously as having radiologically or endoscopically confirmed ulcer disease but were currently endoscopically free of ulcers or scarring. All patients gave their informed consent to be included in the study, which was conducted in accordance with the revised Declaration of Helsinki15 and was approved by the ethics committee of the Centre for Digestive Diseases. Patients were excluded from the study if they had previously failed any H pylori therapy, on the assumption that they belonged to the 'eradication failure' category.4 H pylori status Presence of H pylori infection was assessed endoscopically in every patient by rapid urease test, histological examinations, and microbiological culture of gastric biopsy specimens obtained before the treatment and four weeks after completion of triple therapy. All examinations were performed by the same endoscopist (TJB) with the specimens taken from the gastric antrum and body. The methods used have been described previously16 17 and will be summarised here. One antral specimen was placed in a microtitre tray, which contained buffered urea and an indicator for rapid detection of urease activity as previously described.18 Two antral specimens were taken for microbiological culture, which in our hands is the most sensitive method of detecting the presence of H pylori 16 To assess compliance, patients filled out a standard questionnaire and were interviewed at the six week visit. This has been a successful tool in our hands as measured by eradication success. Patients were asked to grade the side effects of nausea, vomiting, abdominal pain, oral discomfort, diarrhoea, constipation, and rash from nil to severe. Scores were assigned according to severity in the following way: nil, score 0; no side effects experienced: mild, score 1; effects seen but could be disregarded: moderate score 2; effects bad enough to call doctor but could continue treatment and tolerate discomfort: severe, score 3; effects interfered with activities at work; side effects had to be treated or triple therapy had to be discontinued. In practice, a score of 1 was assigned to patients who did not recall side effects when asked 'did you have any side effects?' but who recalled experience of side effects when confronted with a list of individual side effects. A score of 2 or more was given when patients could recall side effects without prompting. For this reason, only scores of 2 or 3 were included as 'clinically significant side effects'.
Statistical analysis H pylori eradication for the triple therapy regimens with famotidine and omeprazole was compared using the x2 test. The differences between mean values of side effects' severity in the two groups and mean number of doses missed by non-compliant patients were determined by Student's t test. All values with p<005 were considered to be statistically significant.
Results
A total of 165 and 171 patients were randomly assigned to the triple therapy plus omeprazole and triple therapy plus famotidine groups respectively. One hundred and twenty five patients returned following the triple therapy+omeprazole regimen (75.8%) and 124 patients who received triple therapy+famoti-dine regimen (72.5%), four weeks after completion of treatment.
Despite a complete phone follow up and remuneration offer a significant number of patients could not be induced to undergo the second endoscopy, often for a variety of economic reasons including preservation of employment status. In addition, as in our previous studies, most (64% of those contacted) claimed they were feeling well and did not wish to proceed with the re-endoscopy. Symptomatic patients were more interested to see whether they still carried the infection20 23 and returned more frequently for rebiopsy. The bias in the study was therefore towards the H pylori positive patients returning with a presumed equivalent 'loss to follow up' occurring in each of the study arms.
Of the patients who returned for reendoscopy 111 in the triple therapy+ omeprazole group and 103 in the triple therapy+famotidine group filled out side effect questionnaire forms. Demographic data and predominant endoscopic diagnosis for all patients included in the analysis of the study was listed. There were no significant demographic or diagnostic differences between the groups of patients using triple therapy with either omeprazole or famotidine (Table I) .
H pylori eradication H pylori was judged to be eradicated in 122 of 125 (97.6%) patients using the triple therapy+omeprazole regimen. Conversely, 1 10 of 124 (89%) patients were cured of Hpylori using triple therapy+famotidine regimen. All three tests used, urease, histological assessment, and microbiology, had to be negative to consider H pylori as being eradicated. There was a significant statistical difference found between these eradication results (p=0-006; X2). The initial sample (165 triple therapy+omeprazole and 171 triple therapy+famotidine patients) would have provided more than 80% power (the usual value used) to the study but the drop out rate was higher than expected so that in the end the power was 70%. Statistically significant results were found, however, and there was a 70% chance of finding them if they were present.
Side effects Severity of side effects experienced by the patients in the two groups was compared. Although this protocol may seem cumbersome it works well in clinical practice perhaps because it is brief. Furthermore it is feasible to combine the three components of triple therapy into a fixed dose combination therapy as a single tablet. This would simplify dosing and enhance compliance. In view of the 95% eradication obtained by Hosking et al 1 1 using a seven day protocol it seems probable that a single tablet could be given for only seven days without significant loss of efficacy and perhaps with further reduction in component doses of triple therapy. Indeed, a one day triple therapy (CBS 240 mg X4; amoxycillin 2 g X4; metronidazole 500 mg X 4) with 40 mg omeprazole, has achieved an eradication of 72%.25 Therefore, there seems to be scope for the reduction not only of triple therapy component doses but also for the reduction in treatment duration.
The use of a simplified protocol using omeprazole and amoxycillin has recently attracted much interest. Variable and often conflicting eradication results have emerged, however, ranging from 28-82%. This led Collins et al 5 to conclude that 'based on present evidence, omeprazole and amoxycillin cannot yet be considered the optimal regimen for eradicating H pylori'. The best of the latest published protocols using the dual therapy achieves an 80-82% eradication in a population selected out for penicillin sensitive patients.23 26 This selection further reduces the eradication to <80% when considering 'all comers'. The major restriction of amoxycillin containing eradication therapies is the existence of penicillin sensitivity in a significant proportion of the population, which will prevent eradication ever approaching 100% described here. Tetracycline containing triple therapy does not suffer from this disadvantage and is therefore amenable to further optimisation.
Side effects of triple therapy have been used as an argument to develop alternative protocols. 26 Side effects of triple therapy are generally minor, however,2S28 reduced by the lower dose triple therapy recently introduced,20 and clinically have been found to be no different by some to side effects of omeprazole alone. 1 " In this study the combination of five times/day triple therapy with omeprazole resulted in infrequent, mild, and certainly clinically insignificant level of adverse reactions. Though not measured directly, it was our impression that the addition of omeprazole shortened duration of dyspeptic symptoms in those patients with ulcers and reflux symptoms.
In vitro metronidazole resistance of H pyloni is currently being invoked as perhaps the major obstacle to more successful eradication when using triple therapy.5 27 29 
